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Abstract
IL-1 plays a key role in disc degeneration and could be a valid
target for inhibiting this process. IL-1 receptor antagonist (IL-1ra)
might be a good candidate to inhibit IL-1 activity. However, many
questions need to be addressed before contemplating therapy in
humans. IL-1 blockade is also a great challenge in osteoarthritis
and results from animal models suggest that IL-1ra may have
beneficial effects. The clinical benefit of a local injection of IL-1ra in
knee osteoarthritis may be limited by the antagonist’s short half-life.
Further studies with longer-lasting antagonists are needed to
explore this new therapeutic approach.
A better understanding of the pathogenesis of inflammatory
arthritis has led to the development and subsequent success-
ful use in humans of biopharmaceuticals blocking, for
example, tumor necrosis factor (TNF)α, CD-20, IL-1 and IL-6
and T-cell co-stimulating factors (CTLA-4). No targeted treat-
ments are available, however, for degenerative rheumato-
logical diseases such as low back pain (LBP) due to inter-
vertebral disc (IVD) degeneration or knee osteoarthritis (OA).
This deficiency may be due in part to our limited under-
standing of the pathogenesis of these diseases; a better
understanding of the pathogenesis of IVD degeneration is a
prerequisite for developing successful biological therapeutic
approaches for patients with LBP.
Current work presented by Freemont’s group [1] has contri-
buted greatly to our understanding of disc remodeling in
degenerative IVD, notably the role of pro-inflammatory
cytokines. They compare the expression of IL-1β and TNFα
as well as their main functional receptors in human IVDs [1].
The most important aspect of this study is the comparison of
non-degenerated, degenerated and herniated samples of
human IVDs. In non-degenerated human IVDs, both cytokines
were expressed at low levels, with an increase in IL-1β
compared to TNFα and a low level of cells positive for TNF
receptor type I [1]. In degenerated human IVDs, although the
protein production of the two cytokines was increased
compared with the non-degenerated samples, the number of
positive cells and the level of gene expression was greater for
IL-1β than for TNFα. Furthermore, IL-1 RI gene expression
and protein production were also increased in degenerated
compared with non-degenerated samples, and a tendency for
decreased synthesis of TNF RI was even observed in
herniated and degenerated human IVDs compared to non-
degenerated samples. These results are very important
because they suggest that IL-1β is more predominant in the
process of IVD degeneration than TNFα [2]. However, they
do not explain the exact roles of both cytokines and raise
more questions than they answer. How do the effects of
TNFα and IL-1β combine to alter the extracellular matrix of
discs? Do they act in the same way in degenerated and
herniated IVDs? Do they act in the same time period? Are
both cytokines involved in pain generation? What is the role
of IL-1α?
These data suggest that IL-1β could be a valid target for
inhibiting disc degeneration and offer an exciting challenge for
developing future therapeutic approaches. Among IL-1
inhibitors, IL-1 receptor antagonist (IL-1ra) might be a candi-
date for preventing IVD degeneration [3]. Indeed, Freemont
and colleagues have shown in monolayer and three-dimen-
sional alginate-cultured resident cells from degenerate IVDs
that IL-1ra down-regulates metal-dependent proteases [4] and,
delivered directly or by gene therapy in explants of degenerated
human IVDs, almost completely eliminates enzyme activity,
thereby decreasing extracellular matrix degradation [2].
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What can we learn from the trials performed
in osteoarthritis with IL-1β β blockers?
It is indeed tempting to compare IVD degeneration to OA
because the profile of cytokine production in human IVDs
looks like the one observed in OA and because resident cells
from discs behave like chondrocyte cells. Some evidence
suggests that IL-1β is not only involved in the structural
damage process of OA but also plays an important role in
pain transmission. Results from in vitro studies and animal
models of OA support the dominant role of IL-1β early in the
disease process. Moreover, intra-articular delivery of anakinra
(recombinant methionyl human receptor antagonist (r-met
HuIL-1ra)) may have beneficial effects on symptoms and
structural modifications in animal models of OA [5-7]. Treated
animals in these studies showed less severe cartilage lesions,
less synovitis, significant reduction in the size of osteophytes,
and significant improvement in clinical indicators of pain and
disease activity.
A first randomized controlled trial in patients with knee OA
demonstrated a good safety profile for one intra-articular
injection of IL-1ra (150 mg, the maximum tolerated dose) [8].
We performed a multicenter, randomized, double-blind,
placebo-controlled study to evaluate the clinical response,
safety, and tolerability of a single intra-articular injection of
anakinra (50 or 150 mg) in 170 patients with symptomatic
OA of the knee [9]. There was no improvement in knee pain,
function, or measures of cartilage turnover with anakinra treat-
ment compared to placebo at the main endpoint (month 1). A
tendency for improvement was noticed in the 150 mg group
at day 4 (in keeping with the short half-life of IL-1ra), sugges-
ting that IL-1 inhibition may be therapeutically relevant.
In the context of LBP, the use of IL-1 blockers is very
attractive, although many questions need to be addressed
before starting to use such therapy: what is the best route of
administration, how many injections should be given, what
types of IL-1 blockers should be used, and at what stage of
the disease should therapy be given?
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